OneMedNet Corporation announced a new AI‑powered imaging platform that will be showcased at the RSNA 2025 conference in Chicago, scheduled for November 30 to December 4. The platform, built on Palantir Foundry and Palantir’s Artificial Intelligence Platform (AIP), is designed to cut cohort‑feasibility time from weeks to minutes, a capability that could accelerate drug‑development timelines for pharmaceutical, medical‑device, and AI companies.
The announcement follows a successful validation session at ISPOR Europe, which took place from November 9 to 12. During that session, customers and prospects praised the platform’s advanced discovery capabilities, underscoring its readiness for regulatory‑grade data use. OneMedNet’s iRWD network now spans more than 2,130 provider sites, 47 million unique patient lives, and 186 million clinical exams and images, giving the company a substantial data advantage in oncology, cardiology, and other high‑growth areas.
CEO Aaron Green highlighted the platform’s impact, saying, “Our momentum at ISPOR strongly validates the strategy we are executing. Customers are now able to determine cohort feasibility in minutes instead of weeks—an acceleration made possible only by the scale, speed, and regulatory‑grade integrity of our iRWD™ network.” The platform’s rapid cohort building is expected to attract a broader base of life‑science partners seeking high‑quality, AI‑ready data for clinical trials and real‑world evidence studies.
By demonstrating the platform at RSNA, OneMedNet aims to accelerate adoption among key industry stakeholders. The event will provide a live showcase of the platform’s user interface and data‑processing capabilities, positioning OneMedNet as a critical partner for life‑science innovation and reinforcing its strategy to monetize its expanding data network through recurring‑revenue subscription models.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.